Secura Bio®

Corporate Profile

Secura Bio® is a pharmaceutical company committed to giving patients access to innovative therapies.

Headquartered in Las Vegas, Nevada, Secura Bio® has global operations in 20 countries.

Leadership

Joseph M. Limber

President & Chief Executive Officer

Mr. Limber has 40 years of experience in Life Sciences and was a co-founder of Secura. His leadership and value creation experience include President/CEO roles at Sequus (acquired by J&J), Praecis (acquired by Glaxo), Aclara Biosciences (acquired by LabCorp), Prometheus Laboratories (acquired by Nestle Health Science) and Genoptix (acquired by NeoGenomics). Mr. Limber’s management experience also includes senior roles at Ciba-Geigy (now Novartis) and Syntex (now Roche).

Mr. Limber’s track record includes building successful commercial organizations, relaunching high-value therapeutics, successful turnarounds and consistently delivering value to investors. Under his leadership, $3.0 billion of financings (private and public), product and M&A transactions were completed. Mr. Limber is a member of the Board of Directors of Secura Bio, Inc. and Xoma Corporation.

Jeffrey A. Ferrell

Board Member

Jeffrey A. Ferrell is the founder of Athyrium (2008) and currently serves as the firm’s Managing Partner. Mr. Ferrell has substantial investment experience in the life sciences sector across a wide range of asset classes and transaction structures.

Prior to forming Athyrium, Mr. Ferrell served in several capacities at Lehman Brothers, including overseeing life sciences investments for Global Trading Strategies (a principal investment group within Lehman) and as Vice President in Lehman Brothers’ Private Equity division focused on life sciences investments. Prior to joining Lehman in 2001, he was Principal at Schroder Ventures Life Sciences (SVLS) based in Boston. Investments Mr. Ferrell has been involved with include: Sequenom, Bioenvision (acquired by Genzyme), Jazz Pharmaceuticals, Orthovita (acquired by Stryker), Nektar Therapeutics, ISTA Pharmaceuticals, Lpath, Auxilium Pharmaceuticals, KaloBios, Fluidigm, and more. Mr. Ferrell graduated with an AB in Biochemical Sciences from Harvard College.

Mr. Ferrell currently serves on the board of Progenity (NASDAQ: PROG).

Mark E. Spring

Financial Consultant

Mr. Spring has 25 years of experience in Life Sciences and was a co-founder of Secura. His financial leadership experience includes capital raising, financial reporting and controls for private and public, domestic and multinational companies. Prior to Secura, Mr. Spring was Chief Financial Officer for Hyperion Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless and Genoptix. In addition, Mr. Spring has extensive M&A experience with significant roles in transactions at Caremark, Dade Behring, Baxter, MedImmune, Prometheus and Genoptix. Prior to his CFO roles, he also held senior level financial positions at Baxter Healthcare and Price Waterhouse.

Mr. Spring earned a B.A. in Business Administration from Monmouth College. He also completed post-graduate studies at the University of Texas, Dallas and is a Certified Public Accountant (active).

Juan Estruch

Head of Corporate Development

Dr. Estruch has over 25 years of experience in Life Sciences and was a co-founder of Secura. He has extensive experience in product assessment, corporate strategy, corporate development and served in increasingly senior management roles. Prior to Secura, Dr. Estruch served in senior positions or as head of corporate development for Ciba-Geigy, Novartis, Diversa, Prometheus and Genoptix. He has a proven track record for identifying under-exploited biopharmaceutical assets that are candidates for repositioning or relaunch.

Dr. Estruch earned a Ph.D. in Biochemistry and Molecular Biology from the University of Essen, Germany and Valencia, Spain. He also earned an MBA from the Fuqua School of Business, Duke University.

David Sidransky, MD

Clinical / Medical Advisor to the CEO

Dr. Sidransky is a renowned oncologist and research scientist who was profiled by TIME magazine in 2001 as one of the top physicians and scientists in America. He is widely recognized for his work with early detection of cancer and the development of patient derived models for drug testing. Dr. Sidransky is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. He has authored more than 600 peer-reviewed publications, and has contributed to more than 65 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of numerous awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Hinda Rosenthal Award and 2017 Team Award presented by the American Association of Cancer Research. Dr. Sidransky was Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for $6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals and Champions Oncology, a developer of precision models for cancer therapy. He is chairman of the board of directors of Ayala and Advaxis and is a member of the BOD of Galmed, Ascentage pharma, and Orgenesis. In addition, Dr. Sidransky served as Director of The American Association for Cancer Research from 2005 to 2008. He received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.

Jamie Sulley, PhD

Senior Vice President — Global Regulatory Affairs and Technology Operations

Dr. Sulley has 32 years of experience in biotech and pharmaceutical industry experience. Prior to joining Secura Bio, she was President and Member of the Board of Directors of Tamir Biotechnology (acquired by Orgenesis), Chief Operating Officer of Tensys Medical (acquired by Shanshi), General Manager for Pharmalink Consulting (acquired by Genpact), and former President of TCSI and JASA. She has grown and expanded pharmaceutical and med tech companies providing global leadership and support for FDA, EMA, MHRA and other health agency regulatory activities at the corporate level. Dr. Sulley has brought drug development programs from proof of concept through to global commercialization for New Chemical Entity (NCE), 505(b)(1) and 505(b)(2) products that have encompassed small molecules, biologics, and combination products leveraging her experience as an accredited FDA reviewer. She holds BS and PHD in Chemistry and a Masters in Public Health from University of Liverpool.

Erik Bokmans

Vice President & General Manager — Europe

Erik has 28 years of international experience in the Biopharma industry, the majority in the areas of hematology and oncology. His extensive commercial and leadership experience was built on sales and marketing roles at Glaxo Wellcome, Roche and Amgen, and more recently with Celgene, where he progressed through a variety of senior and general management roles in the UK, Benelux and the Central Eastern European Region plus multiple strategic European roles. Joining at the start of Celgene’s European lifecycle, he was instrumental in its growth and commercial success, establishing new teams and commercial operations and successfully launching and negotiating national government reimbursement for over 20 new products and indications across multiple geographies.

Mr. Bokmans earned a BSc. Hons in Pharmacology at Kings College, University of London. He also completed post-graduate business studies at the London School of Economics.

Gregory S. Wessels

Vice President, Global Marketing

Mr. Wessels has over 20 years of life sciences experience in sales, marketing and commercialization strategy, most recently having served as Senior Vice President and Chief Commercial Officer of Aprea Therapeutics. Mr. Wessels also held global and regional hematology/oncology positions of increasing responsibility over more than 10 years at Celgene Corporation, culminating as Executive Director, Lymphoma Global Marketing. Prior to joining Celgene he spent 11 years with Sanofi US in sales, marketing and business planning roles.

Mr. Wessels received a BS in Biochemistry from the University of Notre Dame and an MBA from the Kellogg School of Management at Northwestern University.

Investor Contact

Mark Spring

Email: mspring@securabio.com
Phone: (702) 465-4196